{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:16:20Z","timestamp":1792163780309,"version":"4.4.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1097\/wnf.0b013e31824d5115","type":"journal-article","created":{"date-parts":[[2012,3,4]],"date-time":"2012-03-04T00:02:25Z","timestamp":1330819345000},"page":"61-66","source":"Crossref","is-referenced-by-count":44,"title":["Ziprasidone Versus Clozapine in the Treatment of Psychotic Symptoms in Parkinson Disease"],"prefix":"10.1097","volume":"35","author":[{"given":"Luis","family":"Pintor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Valldeoriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Baill\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Mart\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Tolosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210203","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1212\/01.WNL.0000129843.15756.A3","article-title":". Psychiatric comorbidities in patients with Parkinson disease and psychosis.","volume":"63","author":"Marsh","year":"2004","journal-title":"Neurology"},{"key":"R2-2-20210203","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/mds.22589","article-title":"Neuropsychiatric symptoms in Parkinsons disease.","volume":"24","author":"Aarsland","year":"2009","journal-title":"Mov Disord"},{"key":"R3-2-20210203","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2165\/00002512-200825080-00004","article-title":"Pathophysiology and treatment of psychosis in Parkinsons disease: a review.","volume":"25","author":"Zahodne","year":"2008","journal-title":"Drugs Aging"},{"key":"R4-2-20210203","doi-asserted-by":"crossref","first-page":"645","DOI":"10.33588\/rn.4812.2008573","article-title":"Treatment of psychosis in Parkinson.","volume":"48","author":"Duran-Ferreras","year":"2009","journal-title":"Rev Neurol"},{"issue":"suppl 12","key":"R5-2-20210203","first-page":"S23","article-title":"Assessment of EPS and tardive dyskinesia in clinical trials.","volume":"59","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R6-2-20210203","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":". Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R7-2-20210203","first-page":"175","article-title":"Treatment of behavioural disturbances in Parkinsons disease.","volume":"51","author":"Valldeoriola","year":"1997","journal-title":"J Neural Transm"},{"key":"R8-2-20210203","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.euroneuro.2006.08.007","article-title":". Treating dopamimetic psychosis in Parkinsons disease: structured review and meta-analysis.","volume":"17","author":"Frieling","year":"2007","journal-title":"Eur Neuropsychopharmacol"},{"key":"R9-2-20210203","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1517\/13543784.9.4.819","article-title":"Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic.","volume":"9","author":"Daniel","year":"2000","journal-title":"Exp Opinion Invest Drugs"},{"key":"R10-2-20210203","doi-asserted-by":"crossref","first-page":"476","DOI":"10.33588\/rn.4608.2007378","article-title":". Ziprasidone in Parkinsonian dopamine psychosis.","volume":"46","author":"Duran-Ferreras","year":"2008","journal-title":"Rev Neurol"},{"key":"R11-2-20210203","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/01.wnf.0000164297.91643.ff","article-title":". Use of ziprasidone in Parkinsonian patients with psychosis.","volume":"28","author":"Gomez-Esteban","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R12-2-20210203","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clineuro.2006.07.003","article-title":"Treatment of drug-induced psychosis in Parkinsons disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.","volume":"109","author":"Schindehutte","year":"2007","journal-title":"Clin Neurol Neurosurg"},{"key":"R13-2-20210203","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.wnf.0000185826.42443.ee","article-title":". Ziprasidone and psychosis in Parkinson disease.","volume":"28","author":"Micheli","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"R14-2-20210203","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/01.wnl.0000215428.46057.3d","article-title":"; Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.","volume":"66","author":"Miyasaki","year":"2006","journal-title":"Neurology"},{"key":"R15-2-20210203","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":". Accuracy of clinical diagnosis of idiopathic Parkinsons disease: a clinico-pathological study of 100 cases.","volume":"55","author":"Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R16-2-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset progression and mortality.","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"R19-2-20210203","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1176\/jnp.5.1.56","article-title":"Reliability and applicability of movement disorder rating scales in the elderly.","volume":"5","author":"Sweet","year":"1993","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R21-2-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinical.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"R22-2-20210203","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale.","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"R25-2-20210203","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1056\/NEJM199903113401003","article-title":"Low-dose clozapine for the treatment of drug-induced psychosis in Parkinsons disease.","volume":"340","year":"1999","journal-title":"N Engl J Med"},{"key":"R26-2-20210203","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/jnnp.2003.029868","article-title":". Clozapine in drug induced psychosis in Parkinsons disease: a randomized, placebo controlled study with open follow up.","volume":"75","author":"Pollak","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R27-2-20210203","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.schres.2009.05.002","article-title":". Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.","volume":"113","author":"Sacchetti","year":"2009","journal-title":"Schizophr Res"},{"issue":"6","key":"R28-2-20210203","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1177\/0897190011426556","article-title":"Atypical antipsychotic drugs in the treatment of Parkinsons disease.","volume":"24","author":"Friedman","year":"2011","journal-title":"J Pharm Pract"},{"key":"R29-2-20210203","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.55.6.789","article-title":". Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.","volume":"55","author":"Goetz","year":"2000","journal-title":"Neurology"},{"key":"R30-2-20210203","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0006-3223(02)01392-6","article-title":". Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinsons disease.","volume":"52","author":"Breier","year":"2002","journal-title":"Biol Psychiatry"},{"key":"R31-2-20210203","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/01.wnf.0000136891.17006.ec","article-title":". Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis.","volume":"27","author":"Morgante","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R32-2-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/01.WNF.0000236769.31279.19","article-title":". Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinsons disease psychosis.","volume":"29","author":"Merims","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"R33-2-20210203","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/mds.20474","article-title":". Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinsons disease.","volume":"20","author":"Ondo","year":"2005","journal-title":"Mov Disord"},{"key":"R34-2-20210203","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.21116","article-title":". Effect of quetiapine in psychotic Parkinsons disease patients: a double-blind labeled study of 3 months duration.","volume":"22","author":"Rabey","year":"2007","journal-title":"Mov Disord"},{"key":"R35-2-20210203","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinsons disease and other akinetic-rigid syndromes.","volume":"56","author":"Rich","year":"1995","journal-title":"J Clin Psychiatr"},{"key":"R36-2-20210203","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1002\/1531-8257(200011)15:6<1230::AID-MDS1026>3.0.CO;2-9","article-title":". Risperidone in the treatment of dopamine-induced psychosis in Parkinsons disease: an open pilot trial.","volume":"15","author":"Mohr","year":"2000","journal-title":"Mov Disord"},{"key":"R37-2-20210203","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/00002826-200401000-00003","article-title":"Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.","volume":"27","author":"Fernandez","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"R38-2-20210203","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1002\/mds.21091","article-title":". Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinsons disease.","volume":"21","author":"Friedman","year":"2006","journal-title":"Mov Disord"},{"key":"R39-2-20210203","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1016\/S0140-6736(99)00860-0","article-title":"Clozapine in drug-induced psychosis in Parkinsons disease.","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"R40-2-20210203","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1212\/01.WNL.0000068010.82167.CF","article-title":". Longitudinal outcome of Parkinsons disease patients with psychosis.","volume":"60","author":"Factor","year":"2003","journal-title":"Neurology"},{"key":"R41-2-20210203","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.22132","article-title":"Antipsychotic medication treatment for mild hallucinations in Parkinsons disease: positive impact on long-term worsening.","volume":"23","author":"Goetz","year":"2008","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-201203000-00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:26:32Z","timestamp":1786033592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-201203000-00002"}},"subtitle":["A Randomized Open Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31824d5115","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}